Review



rsv strain a 2  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ATCC rsv strain a 2
    Rsv Strain A 2, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/bio_rxiv__64898__2026__03__17__712358-213-59-62?v=ATCC
    Average 94 stars, based on 29 article reviews
    rsv strain a 2 - by Bioz Stars, 2026-07
    94/100 stars

    Images



    Similar Products

    rsv strain a 2  (ATCC)
    94
    ATCC rsv strain a 2
    Rsv Strain A 2, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/bio_rxiv__64898__2026__03__17__712358-213-59-62?v=ATCC
    Average 94 stars, based on 1 article reviews
    rsv strain a 2 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    respiratory syncytial virus rsv strain a 2  (ATCC)
    97
    ATCC respiratory syncytial virus rsv strain a 2
    Respiratory Syncytial Virus Rsv Strain A 2, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/pmc12896270-143-48-54?v=ATCC
    Average 97 stars, based on 1 article reviews
    respiratory syncytial virus rsv strain a 2 - by Bioz Stars, 2026-07
    97/100 stars
    		  Buy from Supplier
    rsv strain a2  (ATCC)
    99
    ATCC rsv strain a2
    Immunological characteristics and immunogenicity of different <t>RSV</t> preF-NPs. The ELISA profiles of RSV preF and preF-NPs binding with the pre-fusion-specific antibody D25 ( A ) and the post-fusion-specific antibody 4D7 ( B ). BALB/c mice ( n = 8 per group) were immunized intramuscularly twice with 5 µg of different preF-NPs on day 0 and day 14, respectively. All preF-NPs vaccines were formulated with Alhydrogel, and the serum was collected on day 28. ( C ) Total IgG titers against antigen preF were measured by endpoint ELISA. GMT ± 95% CI is shown. ( D ) Neutralizing antibody titers were measured by competitive ELISA. GMT ± 95% CI is shown. ( E ) Neutralizing antibody titers against RSV <t>A2</t> strain were measured by live virus neutralization assay. GMT ± 95% CI is shown. Mann-Whitney test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.
    Rsv Strain A2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/pmc12455995-85-0-3?v=ATCC
    Average 99 stars, based on 1 article reviews
    rsv strain a2 - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    rsv strain b18537  (ATCC)
    99
    ATCC rsv strain b18537
    Challenge of SC9-10-NPM in cotton rats experiment #2. Male SPF-grade cotton rats ( n = 6 per group) were immunized on day 0 and day 21 intramuscularly with 3 µg, 15 µg, 30 µg, or 60 µg of SC-9-10-NPM formulated either without adjuvant or in MF59-bio. The PBS control, healthy animal control, and the group receiving inactivated RSV formulated in aluminum hydroxide were included. Serum was collected on day 41 to measure neutralizing antibodies against RSV A2 ( A ) and RSV <t>B18537</t> ( B ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and lung and turbinate bones were collected to measure viral loads ( C and D ). Pathology was measured and scored for individual lung tissues (vs PBS) ( E ), and PreF/PostF IgG ratio was also calculated ( F ). For ( A, B, C, D, and F ), GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. For ( E ), mean ± SD is shown. Ordinary one-way ANOVA was performed to compare each group with PBS control.
    Rsv Strain B18537, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/pmc12455995-85-5-8?v=ATCC
    Average 99 stars, based on 1 article reviews
    rsv strain b18537 - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    6 2 1 4 rsv challenge human rsv strain a2  (ATCC)
    97
    ATCC 6 2 1 4 rsv challenge human rsv strain a2
    Challenge of SC9-10-NPM in cotton rats experiment #2. Male SPF-grade cotton rats ( n = 6 per group) were immunized on day 0 and day 21 intramuscularly with 3 µg, 15 µg, 30 µg, or 60 µg of SC-9-10-NPM formulated either without adjuvant or in MF59-bio. The PBS control, healthy animal control, and the group receiving inactivated RSV formulated in aluminum hydroxide were included. Serum was collected on day 41 to measure neutralizing antibodies against RSV A2 ( A ) and RSV <t>B18537</t> ( B ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and lung and turbinate bones were collected to measure viral loads ( C and D ). Pathology was measured and scored for individual lung tissues (vs PBS) ( E ), and PreF/PostF IgG ratio was also calculated ( F ). For ( A, B, C, D, and F ), GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. For ( E ), mean ± SD is shown. Ordinary one-way ANOVA was performed to compare each group with PBS control.
    6 2 1 4 Rsv Challenge Human Rsv Strain A2, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/us12391957-1805-0-10?v=ATCC
    Average 97 stars, based on 1 article reviews
    6 2 1 4 rsv challenge human rsv strain a2 - by Bioz Stars, 2026-07
    97/100 stars
    		  Buy from Supplier
    rsv strain ch18537  (ATCC)
    99
    ATCC rsv strain ch18537
    Challenge of SC9-10-NPM in cotton rats experiment #2. Male SPF-grade cotton rats ( n = 6 per group) were immunized on day 0 and day 21 intramuscularly with 3 µg, 15 µg, 30 µg, or 60 µg of SC-9-10-NPM formulated either without adjuvant or in MF59-bio. The PBS control, healthy animal control, and the group receiving inactivated RSV formulated in aluminum hydroxide were included. Serum was collected on day 41 to measure neutralizing antibodies against RSV A2 ( A ) and RSV <t>B18537</t> ( B ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and lung and turbinate bones were collected to measure viral loads ( C and D ). Pathology was measured and scored for individual lung tissues (vs PBS) ( E ), and PreF/PostF IgG ratio was also calculated ( F ). For ( A, B, C, D, and F ), GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. For ( E ), mean ± SD is shown. Ordinary one-way ANOVA was performed to compare each group with PBS control.
    Rsv Strain Ch18537, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/pmc12390714-6-2-6?v=ATCC
    Average 99 stars, based on 1 article reviews
    rsv strain ch18537 - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    rsv strain  (ATCC)
    99
    ATCC rsv strain
    Ultraviolet action spectra of light-emitting diodes (LEDs) for infectivity reduction in viruses. ( A ) Influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1). ( B ) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020. ( C ) Human coronavirus (HCoV)-229E. ( D ) Respiratory syncytial virus <t>(RSV)</t> <t>strain</t> long. ( E ) Human metapneumovirus (HMPV) strain TN/83-1211. ( F ) Herpes simplex virus 1 (HSV-1) strain KOS. ( G ) Feline calicivirus (FCV) strain F-9. Viral suspensions were irradiated with LEDs at each peak wavelength at fluences of 2.5 ( A , B ), 3.0 ( C ), 2.0 ( D ), 4.0 ( E ), 5.0 ( F ), and 10.0 mJ/cm 2 ( G ), corresponding to fluences that reduced infectivity by approximately 1 log 10 under U280-LED irradiation. After irradiation, the suspensions were used to infect the host cells. Viral infectivity was measured by plaque-forming unit (PFU) assays. Infectivity reduction is presented as the log 10 PFU ratio. Values are presented as the mean ± SD ( n = 4–6).
    Rsv Strain, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rsv+strain+a+2/pmc12390714-5-2-6?v=ATCC
    Average 99 stars, based on 1 article reviews
    rsv strain - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Immunological characteristics and immunogenicity of different RSV preF-NPs. The ELISA profiles of RSV preF and preF-NPs binding with the pre-fusion-specific antibody D25 ( A ) and the post-fusion-specific antibody 4D7 ( B ). BALB/c mice ( n = 8 per group) were immunized intramuscularly twice with 5 µg of different preF-NPs on day 0 and day 14, respectively. All preF-NPs vaccines were formulated with Alhydrogel, and the serum was collected on day 28. ( C ) Total IgG titers against antigen preF were measured by endpoint ELISA. GMT ± 95% CI is shown. ( D ) Neutralizing antibody titers were measured by competitive ELISA. GMT ± 95% CI is shown. ( E ) Neutralizing antibody titers against RSV A2 strain were measured by live virus neutralization assay. GMT ± 95% CI is shown. Mann-Whitney test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Journal: Journal of Virology

    Article Title: Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses

    doi: 10.1128/jvi.00903-25

    Figure Lengend Snippet: Immunological characteristics and immunogenicity of different RSV preF-NPs. The ELISA profiles of RSV preF and preF-NPs binding with the pre-fusion-specific antibody D25 ( A ) and the post-fusion-specific antibody 4D7 ( B ). BALB/c mice ( n = 8 per group) were immunized intramuscularly twice with 5 µg of different preF-NPs on day 0 and day 14, respectively. All preF-NPs vaccines were formulated with Alhydrogel, and the serum was collected on day 28. ( C ) Total IgG titers against antigen preF were measured by endpoint ELISA. GMT ± 95% CI is shown. ( D ) Neutralizing antibody titers were measured by competitive ELISA. GMT ± 95% CI is shown. ( E ) Neutralizing antibody titers against RSV A2 strain were measured by live virus neutralization assay. GMT ± 95% CI is shown. Mann-Whitney test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001.

    Article Snippet: RSV strain A2 (ATCC) and RSV strain B18537 (ATCC) were produced in HEp-2 cells.

    Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay, Binding Assay, Vaccines, Competitive ELISA, Virus, Neutralization, MANN-WHITNEY

    Immunogenicity of SC-9-10-NPM formulated with different adjuvants. BALB/c mice ( n = 6 per group) were immunized on day 0 and day 14 intramuscularly with 0.2 µg, 1 µg, or 5 µg of SC-9-10-NPM and 1 µg or 5 µg of Arevxy, respectively. SC-9-10-NPM was formulated with PBS (NA group), Alhydrogel, or MF59 biosimilar. Serum was collected on day 28. Neutralizing antibody titers against RSV A2 strain ( A ) and B strain ( B ) were measured by live virus neutralization assay. GMT ± 95% CI is shown. The dotted line represents the antibody titer level by 5 µg of Arevxy. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01.

    Journal: Journal of Virology

    Article Title: Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses

    doi: 10.1128/jvi.00903-25

    Figure Lengend Snippet: Immunogenicity of SC-9-10-NPM formulated with different adjuvants. BALB/c mice ( n = 6 per group) were immunized on day 0 and day 14 intramuscularly with 0.2 µg, 1 µg, or 5 µg of SC-9-10-NPM and 1 µg or 5 µg of Arevxy, respectively. SC-9-10-NPM was formulated with PBS (NA group), Alhydrogel, or MF59 biosimilar. Serum was collected on day 28. Neutralizing antibody titers against RSV A2 strain ( A ) and B strain ( B ) were measured by live virus neutralization assay. GMT ± 95% CI is shown. The dotted line represents the antibody titer level by 5 µg of Arevxy. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01.

    Article Snippet: RSV strain A2 (ATCC) and RSV strain B18537 (ATCC) were produced in HEp-2 cells.

    Techniques: Immunopeptidomics, Virus, Neutralization, Comparison

    Challenge of SC9-10-NPM in cotton rats experiment #1. Male SPF-grade cotton rats ( n = 5 per group) were immunized on day 0 and day 21 intramuscularly with either 60 µg of SC-9-10-NPM formulated in MF59-bio or 60 µg of control vaccine Arexvy. The PBS control and healthy animal control were included. Serum was collected on day 42 to measure neutralizing antibodies against RSV A2 and RSV B ( A ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and turbinate bones, trachea, and lung were collected to measure viral loads ( B ). GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01.

    Journal: Journal of Virology

    Article Title: Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses

    doi: 10.1128/jvi.00903-25

    Figure Lengend Snippet: Challenge of SC9-10-NPM in cotton rats experiment #1. Male SPF-grade cotton rats ( n = 5 per group) were immunized on day 0 and day 21 intramuscularly with either 60 µg of SC-9-10-NPM formulated in MF59-bio or 60 µg of control vaccine Arexvy. The PBS control and healthy animal control were included. Serum was collected on day 42 to measure neutralizing antibodies against RSV A2 and RSV B ( A ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and turbinate bones, trachea, and lung were collected to measure viral loads ( B ). GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01.

    Article Snippet: RSV strain A2 (ATCC) and RSV strain B18537 (ATCC) were produced in HEp-2 cells.

    Techniques: Control, Comparison

    Challenge of SC9-10-NPM in cotton rats experiment #2. Male SPF-grade cotton rats ( n = 6 per group) were immunized on day 0 and day 21 intramuscularly with 3 µg, 15 µg, 30 µg, or 60 µg of SC-9-10-NPM formulated either without adjuvant or in MF59-bio. The PBS control, healthy animal control, and the group receiving inactivated RSV formulated in aluminum hydroxide were included. Serum was collected on day 41 to measure neutralizing antibodies against RSV A2 ( A ) and RSV B18537 ( B ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and lung and turbinate bones were collected to measure viral loads ( C and D ). Pathology was measured and scored for individual lung tissues (vs PBS) ( E ), and PreF/PostF IgG ratio was also calculated ( F ). For ( A, B, C, D, and F ), GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. For ( E ), mean ± SD is shown. Ordinary one-way ANOVA was performed to compare each group with PBS control.

    Journal: Journal of Virology

    Article Title: Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses

    doi: 10.1128/jvi.00903-25

    Figure Lengend Snippet: Challenge of SC9-10-NPM in cotton rats experiment #2. Male SPF-grade cotton rats ( n = 6 per group) were immunized on day 0 and day 21 intramuscularly with 3 µg, 15 µg, 30 µg, or 60 µg of SC-9-10-NPM formulated either without adjuvant or in MF59-bio. The PBS control, healthy animal control, and the group receiving inactivated RSV formulated in aluminum hydroxide were included. Serum was collected on day 41 to measure neutralizing antibodies against RSV A2 ( A ) and RSV B18537 ( B ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and lung and turbinate bones were collected to measure viral loads ( C and D ). Pathology was measured and scored for individual lung tissues (vs PBS) ( E ), and PreF/PostF IgG ratio was also calculated ( F ). For ( A, B, C, D, and F ), GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. For ( E ), mean ± SD is shown. Ordinary one-way ANOVA was performed to compare each group with PBS control.

    Article Snippet: RSV strain A2 (ATCC) and RSV strain B18537 (ATCC) were produced in HEp-2 cells.

    Techniques: Adjuvant, Control, Comparison

    Challenge of SC9-10-NPM in cotton rats experiment #2. Male SPF-grade cotton rats ( n = 6 per group) were immunized on day 0 and day 21 intramuscularly with 3 µg, 15 µg, 30 µg, or 60 µg of SC-9-10-NPM formulated either without adjuvant or in MF59-bio. The PBS control, healthy animal control, and the group receiving inactivated RSV formulated in aluminum hydroxide were included. Serum was collected on day 41 to measure neutralizing antibodies against RSV A2 ( A ) and RSV B18537 ( B ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and lung and turbinate bones were collected to measure viral loads ( C and D ). Pathology was measured and scored for individual lung tissues (vs PBS) ( E ), and PreF/PostF IgG ratio was also calculated ( F ). For ( A, B, C, D, and F ), GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. For ( E ), mean ± SD is shown. Ordinary one-way ANOVA was performed to compare each group with PBS control.

    Journal: Journal of Virology

    Article Title: Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses

    doi: 10.1128/jvi.00903-25

    Figure Lengend Snippet: Challenge of SC9-10-NPM in cotton rats experiment #2. Male SPF-grade cotton rats ( n = 6 per group) were immunized on day 0 and day 21 intramuscularly with 3 µg, 15 µg, 30 µg, or 60 µg of SC-9-10-NPM formulated either without adjuvant or in MF59-bio. The PBS control, healthy animal control, and the group receiving inactivated RSV formulated in aluminum hydroxide were included. Serum was collected on day 41 to measure neutralizing antibodies against RSV A2 ( A ) and RSV B18537 ( B ). RSV A2 (1.0 × 10 6 PFU/animal) was challenged on day 42 via the intranasal route. Animals were sacrificed on day 46, and lung and turbinate bones were collected to measure viral loads ( C and D ). Pathology was measured and scored for individual lung tissues (vs PBS) ( E ), and PreF/PostF IgG ratio was also calculated ( F ). For ( A, B, C, D, and F ), GMT ± 95% CI is shown. Kruskal–Wallis test with Dunn’s multiple comparison test was performed, ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. For ( E ), mean ± SD is shown. Ordinary one-way ANOVA was performed to compare each group with PBS control.

    Article Snippet: RSV strain A2 (ATCC) and RSV strain B18537 (ATCC) were produced in HEp-2 cells.

    Techniques: Adjuvant, Control, Comparison

    Ultraviolet action spectra of light-emitting diodes (LEDs) for infectivity reduction in viruses. ( A ) Influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1). ( B ) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020. ( C ) Human coronavirus (HCoV)-229E. ( D ) Respiratory syncytial virus (RSV) strain long. ( E ) Human metapneumovirus (HMPV) strain TN/83-1211. ( F ) Herpes simplex virus 1 (HSV-1) strain KOS. ( G ) Feline calicivirus (FCV) strain F-9. Viral suspensions were irradiated with LEDs at each peak wavelength at fluences of 2.5 ( A , B ), 3.0 ( C ), 2.0 ( D ), 4.0 ( E ), 5.0 ( F ), and 10.0 mJ/cm 2 ( G ), corresponding to fluences that reduced infectivity by approximately 1 log 10 under U280-LED irradiation. After irradiation, the suspensions were used to infect the host cells. Viral infectivity was measured by plaque-forming unit (PFU) assays. Infectivity reduction is presented as the log 10 PFU ratio. Values are presented as the mean ± SD ( n = 4–6).

    Journal: Viruses

    Article Title: Viral Inactivation by Light-Emitting Diodes: Action Spectra Reveal Genomic Damage as the Primary Mechanism

    doi: 10.3390/v17081065

    Figure Lengend Snippet: Ultraviolet action spectra of light-emitting diodes (LEDs) for infectivity reduction in viruses. ( A ) Influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1). ( B ) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020. ( C ) Human coronavirus (HCoV)-229E. ( D ) Respiratory syncytial virus (RSV) strain long. ( E ) Human metapneumovirus (HMPV) strain TN/83-1211. ( F ) Herpes simplex virus 1 (HSV-1) strain KOS. ( G ) Feline calicivirus (FCV) strain F-9. Viral suspensions were irradiated with LEDs at each peak wavelength at fluences of 2.5 ( A , B ), 3.0 ( C ), 2.0 ( D ), 4.0 ( E ), 5.0 ( F ), and 10.0 mJ/cm 2 ( G ), corresponding to fluences that reduced infectivity by approximately 1 log 10 under U280-LED irradiation. After irradiation, the suspensions were used to infect the host cells. Viral infectivity was measured by plaque-forming unit (PFU) assays. Infectivity reduction is presented as the log 10 PFU ratio. Values are presented as the mean ± SD ( n = 4–6).

    Article Snippet: , , RSV strain long , ATCC , Hep-2 , JCRB.

    Techniques: Infection, Virus, Irradiation

    UV action spectra of light-emitting diodes (LEDs) for inducing viral RNA damage. ( A ) Influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1). ( B ) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020. ( C ) Respiratory syncytial virus (RSV) strain long. ( D ) Human metapneumovirus (HMPV) strain TN/83-1211. The viral suspensions were irradiated with LEDs at each peak wavelength at 10 (SARS-CoV-2 and RSV) or 15 mJ/cm 2 (IAV and HMPV), and the viral RNA was then extracted. RNA damage was assessed using strand-specific RT-qPCR. Values are presented as the mean ± SD ( n = 4–6).

    Journal: Viruses

    Article Title: Viral Inactivation by Light-Emitting Diodes: Action Spectra Reveal Genomic Damage as the Primary Mechanism

    doi: 10.3390/v17081065

    Figure Lengend Snippet: UV action spectra of light-emitting diodes (LEDs) for inducing viral RNA damage. ( A ) Influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1). ( B ) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020. ( C ) Respiratory syncytial virus (RSV) strain long. ( D ) Human metapneumovirus (HMPV) strain TN/83-1211. The viral suspensions were irradiated with LEDs at each peak wavelength at 10 (SARS-CoV-2 and RSV) or 15 mJ/cm 2 (IAV and HMPV), and the viral RNA was then extracted. RNA damage was assessed using strand-specific RT-qPCR. Values are presented as the mean ± SD ( n = 4–6).

    Article Snippet: , , RSV strain long , ATCC , Hep-2 , JCRB.

    Techniques: Virus, Irradiation, Quantitative RT-PCR

    Damage to viral proteins by irradiation with U280 light-emitting diodes (LEDs). ( A ) Non-structural protein 1 (NS1) of influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1). ( B ) Spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020. ( C ) Fusion glycoprotein of respiratory syncytial virus (RSV) strain long. ( D ) Infected cell protein 0 (ICP0) of herpes simplex virus-1 (HSV-1) strain KOS. The top images present the representative results of immunoblotting for each viral protein. Viral suspensions were irradiated with U280-LEDs at the indicated fluences, and proteins were then extracted. Viral proteins were detected by Western blotting using specific antibodies. Values are presented as the mean ± SD ( n = 3–4).

    Journal: Viruses

    Article Title: Viral Inactivation by Light-Emitting Diodes: Action Spectra Reveal Genomic Damage as the Primary Mechanism

    doi: 10.3390/v17081065

    Figure Lengend Snippet: Damage to viral proteins by irradiation with U280 light-emitting diodes (LEDs). ( A ) Non-structural protein 1 (NS1) of influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1). ( B ) Spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020. ( C ) Fusion glycoprotein of respiratory syncytial virus (RSV) strain long. ( D ) Infected cell protein 0 (ICP0) of herpes simplex virus-1 (HSV-1) strain KOS. The top images present the representative results of immunoblotting for each viral protein. Viral suspensions were irradiated with U280-LEDs at the indicated fluences, and proteins were then extracted. Viral proteins were detected by Western blotting using specific antibodies. Values are presented as the mean ± SD ( n = 3–4).

    Article Snippet: , , RSV strain long , ATCC , Hep-2 , JCRB.

    Techniques: Irradiation, Virus, Infection, Western Blot

    UV action spectra of light-emitting diodes (LEDs) for viral protein degradation. ( A ) Representative images of immunoblotting for viral proteins. ( B – E ) UV action spectra of LEDs for the degradation of ( B ) non-structural protein 1 (NS1) of influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1), ( C ) spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020, ( D ) fusion glycoprotein of respiratory syncytial virus (RSV) strain long, and ( E ) infected cell protein 0 (ICP0) of herpes simplex virus-1 (HSV-1) strain KOS. The viral suspensions were irradiated with LEDs at each peak wavelength and a fluence of 10 (for SARS-CoV-2 and RSV) or 15 mJ/cm 2 (for IAV and HSV-1), and the viral proteins were then extracted. Viral proteins were detected by Western blotting using specific antibodies. Values are presented as the mean ± SD ( n = 3–4).

    Journal: Viruses

    Article Title: Viral Inactivation by Light-Emitting Diodes: Action Spectra Reveal Genomic Damage as the Primary Mechanism

    doi: 10.3390/v17081065

    Figure Lengend Snippet: UV action spectra of light-emitting diodes (LEDs) for viral protein degradation. ( A ) Representative images of immunoblotting for viral proteins. ( B – E ) UV action spectra of LEDs for the degradation of ( B ) non-structural protein 1 (NS1) of influenza A virus (IAV) strain A/human/Puerto Rico/8/1934 (H1N1), ( C ) spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Hu/DP/Kng/19-020, ( D ) fusion glycoprotein of respiratory syncytial virus (RSV) strain long, and ( E ) infected cell protein 0 (ICP0) of herpes simplex virus-1 (HSV-1) strain KOS. The viral suspensions were irradiated with LEDs at each peak wavelength and a fluence of 10 (for SARS-CoV-2 and RSV) or 15 mJ/cm 2 (for IAV and HSV-1), and the viral proteins were then extracted. Viral proteins were detected by Western blotting using specific antibodies. Values are presented as the mean ± SD ( n = 3–4).

    Article Snippet: , , RSV strain long , ATCC , Hep-2 , JCRB.

    Techniques: Western Blot, Virus, Infection, Irradiation